progestational

Patients who are not candidates for either surgery or radiation therapy may be treated with progestational agents.

A progestin is a synthetic progestogen that has progestational effects similar to progesterone.

The most common hormonal treatment has been progestational agents, which produce good antitumor responses in as many as 15% to 30% of patients.

Dydrogesterone is characterised by progestational and antiestrogenic activity.

Therefore, use of cyproterone acetate in combination with substances which inhibit CYP3A4 may increase the progestational effects.

Progestational agents have been evaluated as adjuvant therapy in a randomized clinical trial of stage I disease and have been shown to be of no benefit.

Syntex submitted its compound to a laboratory in Madison, Wisconsin, for biological evaluation, and found it was the most active, orally-effective progestational hormone of its time.

The progestational efficacy and potency of dydrogesterone was confirmed by standard test (i.e. delay of menses and induction of withdrawal bleeding).

It showed that women who took a combination of the estrogen ethinyl estradiol and the progestational agent norethindrone acetate experienced a dose-related increase in bone mineral density over two years.

Cyproterone acetate (brand names Androcur, Climen, Diane 35, and Ginette 35) is a synthetic steroid, a potent antiandrogen that also possesses progestational properties.

This can also be accomplished with progestational agents (i.e., medroxyprogesterone), danazol, gestrinone, or gonadotropin-releasing hormone agonists (GnRH), as well as other less well-known agents.

Options with reported efficacy include androgens, progestational agents, gabapentin, SSRIs, selective serotonin norepinephrine inhibitors, alpha adrenergic agonists (e.g., methyldopa, clonidine), beta-blockers, and veralipride (an antidopaminergic agent).

Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone, and acts as an androgen receptor antagonist as well as a weak progesterone receptor agonist with weak progestational and glucocorticoid activity.

Estrogen without a progestational agent is no longer recommended for women who still have a uterus, since unopposed estrogen can stimulate the growth of the uterine lining and increase a woman's risk of developing endometrial cancer.

Lynestrenol has a strong progestational effect on the uterine endometrium (transforming proliferative endometrium into secretory one), inhibits secretion of gonadotropin, suppresses maturation of follicles in the ovaries and ovulation, reduces menstrual bleeding.

W.M. Allen, "Physiology of the corpus luteum, V: the preparation and some chemical properties of progestin, a hormone of the corpus luteum which produces progestational proliferation", Am J Physiol 92 (1930), pp.

It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.